Syntagon Restructures to Further Improve Drug Substance Development Offering
STOCKHOLM--(BUSINESS WIRE)--Syntagon’s Sweden-based operations (Syntagon AB) will focus and strengthen its customer-oriented expertise within drug substance development, quality assurance and regulatory support, while the Group’s Latvian site (SIA Syntagon Baltic) will ramp up its capacity and know-how within the field of preclinical and clinical deliveries of drug substances.